Cargando…

Managing Heart Failure at Home With Point-of-Care Diagnostics

The objective of this paper is development of an inexpensive point-of-care sensor for detecting the primary heart failure marker peptide, NT-proBNP. The device technology is based on an antibody sandwich assay, but with three innovative aspects. First, chemical amplification is carried out via oxida...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IEEE 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630005/
https://www.ncbi.nlm.nih.gov/pubmed/29018639
http://dx.doi.org/10.1109/JTEHM.2017.2740920
_version_ 1783269157521850368
collection PubMed
description The objective of this paper is development of an inexpensive point-of-care sensor for detecting the primary heart failure marker peptide, NT-proBNP. The device technology is based on an antibody sandwich assay, but with three innovative aspects. First, chemical amplification is carried out via oxidation of silver nanoparticles (NPs) attached to signaling antibodies rather than by enzymatic amplification. The electrochemical method is faster and eliminates the need for long-term storage of enzymes. Second, the antibody sandwich is formed on mobile magnetic beads. This enhances the rate of mass transfer of the biomarker and the signaling antibody to the primary detection antibody, which is immobilized on the magnetic beads. Third, the sensor itself is fabricated on a paper platform with screen-printed electrodes. This coupled with assembly by simple paper folding, keeps the cost of the sensor low. Here, we report on two separate assays. The first is based on a simple biotin-streptavidin conjugate, which is a preliminary model for the antibody assay. The results indicate a detection limit of 2.1 pM of silver NPs and an assay time of 7 min. The actual NT-proBNP antibody assay takes somewhat longer, and the dynamic detection range is higher: 2.9–582 nM. On the basis of the results presented in this paper, we conclude that this inexpensive paper-based sensor represents a viable technology for point-of-care testing of NT-proBNP, but nevertheless several challenges remain prior to clinical implementation. These include attaining a lower detection limit and better reproducibility, and optimizing the device for human blood.
format Online
Article
Text
id pubmed-5630005
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher IEEE
record_format MEDLINE/PubMed
spelling pubmed-56300052017-10-10 Managing Heart Failure at Home With Point-of-Care Diagnostics IEEE J Transl Eng Health Med Article The objective of this paper is development of an inexpensive point-of-care sensor for detecting the primary heart failure marker peptide, NT-proBNP. The device technology is based on an antibody sandwich assay, but with three innovative aspects. First, chemical amplification is carried out via oxidation of silver nanoparticles (NPs) attached to signaling antibodies rather than by enzymatic amplification. The electrochemical method is faster and eliminates the need for long-term storage of enzymes. Second, the antibody sandwich is formed on mobile magnetic beads. This enhances the rate of mass transfer of the biomarker and the signaling antibody to the primary detection antibody, which is immobilized on the magnetic beads. Third, the sensor itself is fabricated on a paper platform with screen-printed electrodes. This coupled with assembly by simple paper folding, keeps the cost of the sensor low. Here, we report on two separate assays. The first is based on a simple biotin-streptavidin conjugate, which is a preliminary model for the antibody assay. The results indicate a detection limit of 2.1 pM of silver NPs and an assay time of 7 min. The actual NT-proBNP antibody assay takes somewhat longer, and the dynamic detection range is higher: 2.9–582 nM. On the basis of the results presented in this paper, we conclude that this inexpensive paper-based sensor represents a viable technology for point-of-care testing of NT-proBNP, but nevertheless several challenges remain prior to clinical implementation. These include attaining a lower detection limit and better reproducibility, and optimizing the device for human blood. IEEE 2017-09-04 /pmc/articles/PMC5630005/ /pubmed/29018639 http://dx.doi.org/10.1109/JTEHM.2017.2740920 Text en 2168-2372 © 2017 IEEE. Translations and content mining are permitted for academic research only. Personal use is also permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications_standards/publications/rights/index.html for more information. http://www.ieee.org/publications_standards/publications/rights/oapa.pdf
spellingShingle Article
Managing Heart Failure at Home With Point-of-Care Diagnostics
title Managing Heart Failure at Home With Point-of-Care Diagnostics
title_full Managing Heart Failure at Home With Point-of-Care Diagnostics
title_fullStr Managing Heart Failure at Home With Point-of-Care Diagnostics
title_full_unstemmed Managing Heart Failure at Home With Point-of-Care Diagnostics
title_short Managing Heart Failure at Home With Point-of-Care Diagnostics
title_sort managing heart failure at home with point-of-care diagnostics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630005/
https://www.ncbi.nlm.nih.gov/pubmed/29018639
http://dx.doi.org/10.1109/JTEHM.2017.2740920
work_keys_str_mv AT managingheartfailureathomewithpointofcarediagnostics
AT managingheartfailureathomewithpointofcarediagnostics
AT managingheartfailureathomewithpointofcarediagnostics
AT managingheartfailureathomewithpointofcarediagnostics
AT managingheartfailureathomewithpointofcarediagnostics
AT managingheartfailureathomewithpointofcarediagnostics